NCT04176848 2026-02-18
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT05209529 2024-02-23
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02649686 2023-08-04
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Canadian Cancer Trials Group
Phase 1 Completed